Black Diamond Therapeutics
BDTX
101 hedge funds and large institutions have $206M invested in Black Diamond Therapeutics in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 37 reducing their positions, and 14 closing their positions.
1% less funds holding
Funds holding: 102 → 101 (-1)
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
2.92% less ownership
Funds ownership: 70.24% → 67.32% (-2.9%)
33% less capital invested
Capital invested by funds: $308M → $206M (-$102M)
38% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 37
39% less call options, than puts
Call options by funds: $433K | Put options by funds: $705K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$2.45M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$1.92M |
| 3 |
Morgan Stanley
New York
|
+$1.58M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.57M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.55M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.56M |
| 3 |
DM
Deerfield Management
New York
|
-$2.84M |
| 4 |
Two Sigma Investments
New York
|
-$1.16M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$907K |
BDTX Hedge Fund Activity: Q3 2021 in Review
101 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q3 2021, worth a combined $206M — down 33% from $308M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of BDTX and 13 opened new positions — a net loss of 1 holder — while 37 trimmed existing stakes and 23 added.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $2.45M. The largest seller was Vanguard Group, cutting an estimated $4.55M.
- 101 institutional investors held Black Diamond Therapeutics (BDTX) as of Q3 2021, down from 102 in Q2 2021.
- Funds reported $206M of Black Diamond Therapeutics stock for Q3 2021, down 33% quarter-over-quarter.
- 13 funds opened new Black Diamond Therapeutics positions in Q3 2021 and 14 closed out, a net change of -1 holder.
- The largest Black Diamond Therapeutics buyer in Q3 2021 was MPM BioImpact, an estimated $2.45M added.
- The largest Black Diamond Therapeutics seller in Q3 2021 was Vanguard Group, an estimated $4.55M sold.
Based on aggregated 13F filings for Q3 2021.